News
Injectable antibodies targeting PCSK9 have failed to take off as expected in the cholesterol-lowering market, but Merck & Co hopes to do much better with an oral alternative. MK-0616 has been ...
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a pair of phase 3 wins for enlicitide decanoate in patients with ...
Merck & Co., Inc. (NYSE:MRK) is one of the 10 best defensive stocks to buy in a volatile market. On July 2, UBS reiterated a ...
RAHWAY, N.J., June 09, 2025--Merck Announces Positive Topline Results from Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults with Hyperlipidemia ...
In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant and clinically meaningful cuts in low ...
Merck’s pipeline includes Phase 3 PCSK9 inhibitor and GLP-1/glucagon receptor agonist. From tariffs to inflation, macro risks are rising—Matt Maley reveals how he’s trading it all, ...
In this analysis, we explore the potential upside for Merck despite its short-term hurdles. Newsletters Amazon Prime Day Share a News Tip. Featured. ... is intended to be the first oral PCSK9 ...
Enlicitide, a novel macrocyclic peptide, has the potential to be the first approved oral PCSK9 inhibitor. Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results